Clinical trial
Evaluation of Treatment With Viusid in Post-COVID-19 Syndrome
NCT06437210 is registered in ClinicalTrials.gov with Catalysis SL as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Evaluation of Treatment With Viusid in Post-COVID-19 Syndrome
- Lead sponsor
- Catalysis SL
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- February 15, 2022
- Completion date
- March 15, 2024
- Enrollment
- 200 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
cough, covid-19, dyspnea, fatigue, inflammation, post-covid-19 syndrome